Date: 2013-03-19
Type of information: R&D agreement
Compound: potential drug targets and drug candidates in fibrosis-related inflammatory diseases and CNS disorders
Company: UCB (Belgium) Five Prime Therapeutics (USA)
Therapeutic area: CNS diseases - Inflammatory diseases
Type agreement: R&D
Action mechanism:
Disease: fibrosis-related inflammatory diseases, central nervous system disorders
Details: UCB and Five Prime Therapeutics have entered into a strategic collaboration for the discovery of innovative biologics targets and therapeutics in the areas of fibrosis-related inflammatory diseases and central nervous system (CNS) disorders. This collaboration gives UCB exclusive access to FivePrime’s drug discovery platforms in up to five programs to identify new targets and disease mechanisms.
Under the terms of the agreement, UCB and FivePrime will collaborate to design assays to screen FivePrime’s comprehensive, proprietary library of approximately 5600 functional secreted proteins and transmembrane receptor proteins (ligand traps). FivePrime will apply its technology platforms to identify potential drug targets and drug candidates in fibrosis-related inflammatory diseases and CNS disorders. UCB has an option to license exclusively rights to selected protein targets discovered by FivePrime in the collaboration.
Financial terms: FivePrime will be eligible to receive approximately $16 million from a combination of an upfront fee, technology access fees, research funding and success-based research milestone payments. In addition, FivePrime would be eligible for potential option exercise fees and product-related milestone payments, as well as tiered royalties on global net sales on future products related to each licensed protein.
Latest news:
